Delfi Diagnostics Inc. recently commissioned Milliman to estimate the utilization and cost for screening for lung, breast, colorectal, and cervical cancer by insurance market segment. We analyzed Milliman’s Consolidated Health Cost Guidelines Sources Database (CHSD) to summarize data from 2021 and 2022 for the commercial, managed Medicaid, and Medicare Advantage insurance market segments. For Medicare fee-for-service, we used calendar-year 2021 data from the Centers for Medicare and Medicaid Services’ standard analytical files 5% sample. The paper is organized as follows: 

• Results
• Background
• Methodology and assumptions
• Discussion

This report was commissioned by Delfi Diagnostics Inc.